Humanigen's mAb improves outcomes in hospitalized COVID-19 patients

By The Science Advisory Board staff writers

Humanigen is highlighting results from a phase III trial that show that its monoclonal antibody (mAb), lenzilumab, improves outcomes in hospitalized COVID-19 patients by keeping them off mechanical ventilators.

The study found that patients who received the drug in combination with other treatments including steroids and remdesivir had a 54% greater relative likelihood of survival without the need for mechanical ventilation compared with patients receiving placebo and other treatments.

Humanigen plans to submit an emergency use authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for lenzilumab.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?